Theralase's Rutherrin Shows 100-Fold Cancer Cell Kill Enhancement in Preclinical Studies
核心洞察
Theralase's X-ray-activated drug Rutherrin demonstrated a 100-fold increase in cancer cell kill compared to radiation therapy alone across multiple preclinical cancer models.
The ruthenium (搜索)-based compound showed greater than 10-fold preferential tumor uptake over healthy brain tissue in glioblastoma models and significantly prolonged survival.
Rutherrin induced complete tumor regression in colorectal models and provided long-term protection against tumor rechallenge through immune activation mechanisms.
Theralase Technologies (搜索) has reported promising preclinical results for its lead drug candidate Rutherrin, an X-ray-activated cancer therapeutic that demonstrated a 100-fold increase in cancer cell kill compared to radiation therapy alone. The findings, published in the International Journal of Radiation Oncology - Biology - Physics, support the compound's potential as a breakthrough treatment for aggressive cancers.
Enhanced Tumor Destruction Across Multiple Cancer Types
The study evaluated Rutherrin, a ruthenium (搜索)-based small molecule formulated with recombinant human transferrin (搜索), across several preclinical cancer models including glioblastoma multiforme (搜索), lung cancer (搜索), colorectal cancer (搜索), and lymphoma (搜索). The radiation-activated compound achieved significant improvements in tumor destruction through multiple mechanisms.
"The preclinical research has demonstrated the utility of X-ray-activated Rutherrin as a preferred addition to radiation therapy to increase efficacy, improve local tumor control, overcome treatment resistance and stimulate systemic immunity," stated Mark Roufaiel, Ph.D., Research Scientist at Theralase.
Dual Mechanism of Action
Rutherrin operates through both direct cytotoxic effects and immune activation. The compound increased Reactive Oxygen Species (ROS) production and stimulated immune-related cytokine and chemokine expression, driving both immediate and immune-mediated cancer cell death. Additionally, Rutherrin modulated drug efflux pathways, helping overcome mechanisms associated with multidrug and radiation resistance.
In colorectal cancer (搜索) models, the combination of Rutherrin with radiation induced complete tumor regression and provided long-term protection against tumor rechallenge, demonstrating durable immune memory formation.
Tumor Selectivity and Survival Benefits
In glioblastoma multiforme (搜索) models, Rutherrin demonstrated greater than 10-fold preferential tumor uptake over healthy brain tissue. Both GBM and lung cancer (搜索) models showed significantly prolonged survival compared to radiation therapy alone, highlighting the compound's therapeutic potential across different cancer types.
"The patented compound amplifies radiation's direct cytotoxic effects, while stimulating a durable immune response, positioning it as a potential breakthrough in the management of aggressive cancers," said Roger DuMoulin-White, President and Chief Executive Officer of Theralase.
Clinical Development Timeline
Theralase plans to advance Rutherrin toward clinical trials following completion of regulatory requirements. Chief Scientific Officer Arkady Mandel, M.D., Ph.D., D.Sc., outlined the company's development strategy: "Next steps in our research program are to complete Good Laboratory Practice toxicology studies in 2026, paving the way for the launch of clinical development targeting GBM, NSCLC (搜索), pancreatic, lymphoma (搜索) and colorectal cancers."
The clinical stage pharmaceutical company specializes in developing light, radiation, sound and drug-activated therapeutics for treating cancer, bacteria and viruses, with a focus on minimizing impact on surrounding healthy tissue.